Galectin Therapeutics is hosting a virtual key opinion leader (KOL) event to discuss the unmet needs in treating MASH cirrhosis and portal hypertension, positioning the company as a thought leader in ...

Please provide your email address to receive an email when new articles are posted on . Xarelto improved portal hypertension complication-free survival in patients with cirrhosis and moderate liver ...

Gastrointestinal bleeding is common among people with cirrhosis due to a complication called portal hypertension. This is elevated blood pressure in the veins that lead to your liver. Cirrhosis is ...

NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (GALT) (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and ...

Spleen stiffness measurement (SSM) offers a noninvasive method to diagnose portal hypertension in BCR::ABL1-negative MPN patients, potentially improving patient management. SSM captures hepatic ...

Actively identifying the risk factors and predictive indicators associated with portal vein thrombosis (PVT) in liver cirrhosis (LC) can enable early diagnosis and treatment, which is of great ...